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Summary 
 
The innermost layer of a vessel, the endothelium, forms an interface 
between the circulating blood in the vascular lumen and the vessel wall. The 
endothelium functions as a.) a physical barrier between the blood and the 
vessel; b.) a vital source of enzymes activating and deactivating 
cardiovascular hormones; c.) a site of production of relaxing and contracting 
factors; and d.) a source of growth inhibitors and promoters.  
Risk factors such as diabetes, hypertension, obesity and smoking can 
disturb the integrity of the endothelium rendering it dysfunctional. A 
dysfunctional endothelium is characterized by a decreased endothelium-
dependent relaxation which in turn facilitates the entry and oxidation of 
circulating lipoproteins and monocytes through the endothelium into the 
intima. The advancing accumulation of lipoproteins and monocytes into the 
intima eventually gives rise to an early atherosclerotic lesion which later 
develops into a necrotic core and a fibrous cap and ultimately becomes an 
advanced plaque at risk of rupture. Rupture of unstable plaques is responsible 
for coronary thrombosis, the main cause of unstable angina, acute myocardial 
infarction, and sudden cardiac death. 
Percutaneous transluminal coronary angioplasty is a clinical procedure 
routinely employed to revascularise occluded vessels. Following 
percutaneous transluminal coronary angioplasty a tube-like metal structure, a 
stent, is inserted into the vessel to prevent it from occluding once again. 
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Stents are commonly coated with drugs orientated at inhibiting the excessive 
proliferation of vascular smooth muscle responsible for restenosis. 
 Unlike for restenosis, recent evidence has shown that the incidence of 
in stent thrombosis has not decreased following the advent of drug eluting 
stents.  Rapamycin which is widely used for coating stents has been shown to 
induce the expression of TF, the key initiator of the coagulation cascade. This 
finding shed new light on the possible causes for the occurrence of stent 
thrombosis. 
In the first part of this thesis we characterised the impact of paclitaxel, 
the main alternative to rapamycin, on TF expression in human endothelial 
cells. Indeed, paclitaxel enhanced thrombin-induced endothelial TF protein 
expression in a concentration- and time-dependent manner. A concentration 
of 10-5 mol/L elicited a 2.1-fold increase in TF protein and a 1.6-fold increase 
in cell surface TF activity. The effect was similar after a 1 h as compared to a 
25 h pretreatment period. Real-time polymerase chain reaction revealed that 
paclitaxel increased thrombin-induced TF mRNA expression. Paclitaxel 
potently activated c-Jun terminal NH2 kinase (JNK) as compared to thrombin 
alone, while the thrombin-mediated phosphorylation of p38 and extracellular 
signal-regulated kinase remained unaffected. Similar to paclitaxel, docetaxel 
enhanced both TF expression and JNK activation as compared to thrombin 
alone. The JNK inhibitor SP600125 reduced thrombin-induced TF expression 
by 35%. Moreover, SP600125 blunted the effect of paclitaxel and docetaxel 
on thrombin-induced TF expression. 
Paclitaxel increases endothelial TF expression via selective activation 
of JNK. This observation provides novel insights into the pathogenesis of 
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thrombus formation after paclitaxel-eluting stent deployment and may have an 
impact on drug-eluting stent design. 
In the second part of this thesis we directed our efforts at 
characterising the potential application of Dimethyl sulfoxide (DMSO) as a 
novel agent to be used for stent coating. DMSO is used for preservation of 
hematopoietic progenitor cells and infused into patients undergoing bone 
marrow transplantation. Despite of its intravenous application, the impact of 
DMSO on vascular cells has not been assessed. In this study we found that 
DMSO inhibited TF expression in human endothelial cells, monocytes, and 
VSMC. Real-time PCR revealed that inhibition of TF expression occurred at 
the mRNA level. This effect was mediated by reduced activation of the MAP 
kinases JNK and p38, but not ERK. In vivo, DMSO treatment suppressed TF 
activity and prevented thrombotic occlusion in a mouse model of carotid artery 
photochemical injury. DMSO also inhibited VSMC proliferation and migration 
in a concentration-dependent manner; moreover, it prevented rapamycin and 
paclitaxel-induced upregulation of TF expression. 
As the use of DMSO is established in different areas of modern 
medicine, we propose this drug as a novel strategy for treating acute coronary 
syndromes; in particular, DMSO seems to represent an attractive compound 
for application on drug-eluting stents, either alone or in combination with 
rapamycin or paclitaxel.  
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Zusammenfassung 
 
 
Das Endothel als innerste Schicht eines Blutgefäßes stellt eine 
Verbindung zwischen dem Blutstrom und dem Rest der Gefäßwand dar. Es 
fungiert als eine physikalische Barriere zwischen Blut und Gefäß, dient als 
Quelle für Wachstumsfaktoren –und Inhibitoren sowie für Enzyme, die 
kardiovaskuläre Hormone sowohl aktivieren als auch deaktivieren, und ist an 
der Produktion von Kontraktions- bzw. Relaxations-Faktoren beteiligt. 
Risikofaktoren wie Daibetes, Hypertonie, Adipositas und Rauchen 
stören die Integrität des Endothels und führen zum Verlust der Funktionalität. 
Eine endotheliale Dysfunktion wird durch eine reduzierte NO Synthese 
gekennzeichnet, was wiederum die Aufnahme und Oxidierung zirkulierender 
Lipoproteine und Monozyten durch das Endothel in die Intima erleichtert. 
Diese vortschreitende prozess führt möglicherweise zu einer frühen 
arteriosklerotischen Läsion, welche sich mit der Zeit zu einer plaque mit 
nekrotischem Kern und fibroider Schale entwickelt, woraus im weiteren 
Verlauf eine plaque mit gefahr der ruptur entstehen kann. Die Ruptur eine 
instabilen Plaque ist verantwortlich für koronare Thromben, die 
Hauptursachen für ein akutes coronares syndrom. 
 Perkutane transluminale koronare Angioplastie ist ein in der Klinik 
routinemäßig eingesetztes Verfahren zur Revaskularisierung verschlossener 
Gefäße. Daran angeschlossen ist die Einlage einer als Stent bezeichneten 
röhrenförmigen Struktur, was das wiedereröffnete Gefäß vor erneutem 
Verschluß bewahren soll. Stents sind gewöhnlich mit Substanzen beschichtet, 
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welche die für eine Restenose ursächliche excessive Proliferation glatter 
Gefäßmuskulatur unterbindet.  
Wie neulich gezeigt werden konnte ist, im Gegensatz zu Restenose, 
die Inzidenz für In-Stent-Thrombosen durch die Anwendung von sogenannten 
„Drug eluting stents“ nicht gesunken. Es konnte nachgewiesen werden, dass 
das vielfach zur Beschichtung von Stents verwendete Rapamycin die 
Expression von TF, Hauptinitiator der Koagulationskaskade, induziert, was ein 
neues Licht auf mögliche Ursachen für das Auftreten von In-Stent-
Thrombosen wirft. 
  
Im ersten teil dieser Arbeit charakterisieren wir die Auswirkungen des 
als alternativ zu Rapamycin vorwiegend verwendeten Paclitaxel auf die TF-
Expresssion in menschlichen Endothelzellen. In der Tat steigert Paclitaxel die 
durch Thrombin induzierte endotheliale TF Protein Expression sowohl 
konzentrations -als auch zeitabhängig. Eine Konzentration von 10-5 mol/l 
erbrachte eine 2,1-fache Erhöhung in Bezug auf TF Protein und einen 1,6 
fachen Anstieg der TF Oberflächenaktivität. Die Prästimulation für 1h ergab 
im Vergleich zu einer Vorbehandlung für 25 h keinen wesentlichen 
Unterschied. Anhand RT-PCR konnte gezeigt werden, dass Paclitaxel die 
durch Thrombin induzierte TF mRNA Expression ebenfalls erhöht. Darüber 
hinaus potenzierte Paclitaxel die Aktivierung der c-Jun terminalen NH2 Kinase 
(JNK) durch Thrombin, wohingegen die durch Thrombin vermittelte 
Phosphorilierung von p38 und der extrazellulären signal-regulierten Kinase  
(ERK) unter Zugabe von Paclitaxel unverändert blieb. Docetaxol steigerte, 
ähnlich dem Paclitaxel, sowohl TF Expression als auch JNK Aktivierung im 
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Vergleich zur alleinigen Applikation von Thrombin. Der JNK Inhibitor 
SP600125 konnte die Thrombin-induzierte TF Expression um 35 % 
reduzieren. Im weiteren wurde durch SP600125 der Effekt von sowohl 
Paclitaxel als auch Docetaxel bezüglich TF Expression verschleiert.  
  
Schwerpunkt des zweiten Teils der Arbeit war die Untersuchung von 
Dimethyl Sulfoxid (DMSO) als potentielle neue Substanz zur coating von 
Stents. DMSO wird zur Konservierung von hämapoetischen Stammzellen 
verwendet und Patienten vor Knochenmarktransplantation infundiert. Trotz 
seiner intravenösen Anwendung wurde die Auswirkung von DMSO auf 
vaskuläre Zellen noch nicht untersucht. In dieser Studie konnte gezeigt 
werden, dass DMSO die TF Expression in menschlichen Endothelzellen, 
Monozyten und VSMC unterdrückt. RT-PCR zeigte die Inhibition die TF 
Expression auf mRNA Ebene, was durch die reduzierte Aktivierung der MAP 
Kinasen JNK und p38, jedoch nicht ERK, vermittelt wurde. In vivo unterdrückt 
DMSO die TF Aktivität und verhinderte im Maus-Modell einen thrombotischen 
Verschluß. Darüber hinaus inhibierte DMSO konzentrationsabhängig die 
Proliferation und Migration von glatten Gefäßmuskelzellen, vielmehr es 
verhindertees die Rapamycin bzw. Paclitaxel induzierte Hochregulation der 
TF Expression. 
  
Da DMSO auf unterschiedlichem Gebiet der modernen Medizin bereits 
etabliert zur Anwendung kommt, empfehlen wir diese Substanz als 
neuwertiges Verfahren zur Behandlung eines Akutem Koronarsyndrom; im 
speziellen, DMSO scheint ein attraktives Mittel zur Beschichtung von Drug-
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eluting Stents zu sein, entweder allein oder in Kombination mit Rapamycin 
oder Paclitaxel.               
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Introduction 
 
I: Overview of the cardiovascular system. 
 
The cardiovascular system is an organ system that moves substances 
to and from cells and is composed by the heart, the vasculature and blood 
(Figure 1). The first scientific study reporting the existence and function of the 
cardiovascular system dates back to 1628 and was published by William 
Harvey. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of the pulmonary and systemic circulation 
 
In this scientific report entitled “Exercitatio Anatomica de Motu Cordis 
et Sanguinis in Animalibus” (An Anatomical Exercise on the Motion of the 
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Heart and Blood in Animals), William Harvey described the complete 
circulation and looked upon the heart, not as a mystical organ, but as a pump 
analyzable along mechanical lines. He also measured the amount of blood 
which it sent out to the body. He observed that with each heart beat two 
ounces of blood leave the heart. Moreover he described the one-way valves 
in the heart, like those in the veins, and indicated that, following the 
pulmonary circulation, the blood goes out to all parts of the body through the 
arteries and returns by way of the veins. The blood thus makes a complete 
closed circuit. There was, however, one part of the vasculature which Harvey 
did not observe -the capillary vessels-. It was in fact not until 1660, that 
Marcello Malpighi saw the blood moving in the capillary vessels of the frog's 
lung, and thus supplied the missing link in Harvey's proof of the circulation of 
the blood. 
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II: The endothelium. 
 
The endothelium is the layer of thin, flat cells that lines the interior 
surface of blood vessels, forming an interface between circulating blood in the 
lumen and the rest of the vessel wall. Not only it functions as a physical 
barrier between the blood and the vessel wall but it also serves as a.) a 
physical barrier between the blood and the vessel; b.) a vital source of 
enzymes activating and deactivating cardiovascular hormones; c.) a site of 
production of relaxing and contracting factors; and d.) a source of growth 
inhibitors and promoters.  
Nitric oxide is a potent vasodilator and inhibitor of platelet function it is 
often released together with prostacyclin, which exerts similar effects (Figure 
2). Nitric Oxide and prostacyclin play an important protective role in the 
coronary circulation by mediating vasodilation and inhibiting platelet activation 
(Figure 2). Moreover, the endothelium also releases contracting factors such 
as endothelin-1 and thromboxane A2 (Figure 2); (Luscher, Tanner et al. 1993; 
Yang, Arnet et al. 1994; Ming, Barandier et al. 2004). 
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Figure 2: Overview of vasoactive substances. Nitric oxide (NO) produced by nitric oxide 
synthase (NOS) exerts relaxation and possibly antiproliferation effects by activating cGMP. 
The products of Cyclooxygenase enzymes elicit both vasoconstriction and vasorelaxation; 
prostacyclin (PGI2) causes vasorelaxation via the formation of cAMP, while Thromboxane A2 
(TXA2) and prostaglandin H2 (PGH2) elicit vasoconstriction through the TXA2/PGH2 receptor 
(TX). Cyclooxygenase can also be a source of superoxide (O2) which scavenges NO. 
Endothelin (ET) can activate endothelial receptors (ETB-receptors) in the endothelial cell 
membrane, which are linked to the production of NO and prostacyclin.  Furthermore, 
endothelin activates vascular smooth muscle cell receptors (ETA and ETB receptors), which 
mediate profound contraction and proliferation under certain conditions. ECE= endothelin 
converting enzyme; bET-1= big endothelin-1; EDHF= endothelial derived hyperpolarising 
factor; L-Arg= L-Arginine. 
  
bET-1 ET-1
ECE
Cyclooxygenase NOS
L-Arg EDHFNO
TXA2 PGH2
cAMP cGMP
Contraction Relaxation
ETA ETB
TX TX
O2- PGI2
Endothelium
Vascular Smooth 
Muscle
ET-1
ETB
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Because of its strategic anatomic position, the endothelium is a primary 
target for injuries and cardiovascular risk factors. In particular, aging, low 
density lipoproteins, hypertension, diabetes, and ischemia alter endothelium 
function. Alterations of endothelial function may contribute to vasospasm, 
thrombus formation, and vascular proliferation and in turn myocardial 
ischemia, all common events in patients with coronary artery disease. 
An altered or dysfunctional endothelium is characterized by a 
decreased synthesis of Nitric oxide which in turn facilitates vessel wall entry 
and oxidation of circulating lipoproteins and monocyte as well as causing 
smooth cell proliferation (Fuster, Moreno et al. 2005). The growing mass of 
cells and proteins which accumulates in the intima gives rise to an early 
atherosclerotic lesion (Figure 3). Continuous exposure to pro-atherogenic 
environment will increase chemotaxis of monocytes leading to lipid 
accumulation, necrotic core, and fibrous cap formation, ultimately turning the 
early plaque into an advanced plaque which is unstable and at risk of rupture 
(Figure 3).  Rupture of unstable plaques is responsible for coronary 
thrombosis, the main cause of unstable angina, acute myocardial infarction, 
and sudden cardiac death (Fuster, Moreno et al. 2005).  
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Figure 3: Schematic representation of the evolution of an atherosclerotic plaque. Healthy 
endothelium becomes dysfunctional and nitric oxide production decreases. Infiltration and 
oxidation of lipids and lipoproteins through the endothelium occurs and causes intimal 
thickening. Advancing infiltration of lipids and lipoproteins results in plaque formation which 
later becomes unstable and eventually ruptures.   
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III: The role of tissue factor in thrombosis. 
 
The understanding of the mechanisms regulating Tissue Factor (TF) in 
vascular cells has deepened considerably over the last years. TF has been 
recognized to be involved in the pathogenesis of cardiovascular diseases and 
therefore therapeutic strategies to specifically interfere with TF are being 
developed.  
TF has long been known for being the key initiator of the coagulation 
cascade, it binds factor VIIa resulting in activation of factor IX and factor X, 
ultimately leading to thrombus generation and fibrin formation (Figure 4). 
 
 
Figure 4: Tissue factor: A key regulator of coagulation. Tissue factor (TF) is a key initiator of 
the coagulation cascade. Formation of a complex with factor VIIa (FVIIa) leads to activation of 
factor IX (FIX) and factor X (FX), resulting in thrombin generation and, ultimately, clot 
formation. Tissue factor pathway inhibitor (TFPI), the endogenous inhibitor of TF activity, is 
synthesized and secreted mainly by endothelial cells. TFPI binds to FXa and thereby inhibits 
TF/FVIIa activity (Steffel J et al Circulation 2006;113:722-731) 
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The TF gene consists of 6 exons (Mackman, Morrissey et al. 1989; 
Morrissey, Gregory et al. 1989) and presents one predominant transcript as 
well as at least one alternatively spliced form (Bogdanov, Balasubramanian et 
al. 2003). TF, a 47-kDa protein, is expressed in both vascular and nonvascular 
cells. Congruent to its physiological role, normally there is no direct contact 
between TF and the bloodstream. In the vessel wall, TF is constitutively 
expressed only by vascular smooth muscle cells leading to rapid initiation of 
coagulation in the event of an injury. In contrast, other vascular cells such as 
endothelial cells and monocytes only express TF in the presence of specific 
mediators like thrombin or TNF-α. The coagulation cascade is initiated as 
soon as TF comes into contact with circulating activated factor VII (VIIa), 
resulting in the TF-FVIIa complex (Figure 4). Alternatively, TF can bind 
inactive factor VII and form the TF-FVII complex, which is converted to TF-
FVIIa by FVIIa or already formed TF-FVIIa. The TF-VIIa complex activates 
factor IX, which in turn activates factor X; alternatively, factor X is directly 
converted to factor Xa by TF-FVIIa. In complex with factor Va and calcium, 
Factor Xa catalyzes the conversion of prothrombin to thrombin, thereby 
leading to fibrin formation, platelet activation, and, ultimately, generation of a 
thrombus (Steffel, Luscher et al. 2006).  
Increased levels of TF antigen and activity have been detected in 
atherectomy specimens of patients with unstable angina or myocardial 
infarction (Annex, Denning et al. 1995). Furthermore, in acute coronary 
syndromes, plasma concentrations of inflammatory cytokines such as TNF-α 
and interleukins are indeed increased at the site of coronary artery occlusion 
to such an extent that TF is induced in vascular cells (Maier, Altwegg et al. 
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2005). In view of these findings it is reasonable to postulate that the 
circulating leukocytes and platelets as well as vascular cells may contribute to 
the heightened levels of TF measured in the plasma of patients with unstable 
angina (Soejima, Ogawa et al. 1999). 
Induction of TF expression occurs through a wide array of mediators; 
however, most mediators exert their effect on TF via a limited subset of 
signalling pathways. The MAP kinases p38, p44/42 (ERK), and c-jun terminal 
NH2-kinase (JNK) mediate TNF-α–induced, histamine-induced, and thrombin-
induced TF expression (Mechtcheriakova, Schabbauer et al. 2001; Eto, Kozai 
et al. 2002; Steffel, Akhmedov et al. 2005; Steffel, Hermann et al. 2005), while 
the effect of vascular endothelial growth factor (VEGF) is mediated by p38 and 
ERK (Mechtcheriakova, Schabbauer et al. 2001). In addition, TNF-α and 
VEGF are known to induce TF expression through activation of protein kinase 
C as well (Mechtcheriakova, Schabbauer et al. 2001). The small G-protein 
RhoA and PI3-Akt pathways have also been shown to modulate TF 
expression in response to specific stimuli (Viswambharan, Ming et al. 2004). 
In fact reconstituted-HDL inhibits thrombin-induced TF expression via 
inhibition of RhoA and stimulation of PI3K (Viswambharan, Ming et al. 2004). 
Percutaneous coronary intervention is an invasive clinical procedure 
commonly used to revascularise occluded coronary arteries of patients which 
suffered an acute myocardial infarction. Following revascularisation stents – 
cylinder-like shaped “tubes” designed with the intent of preventing or delaying 
the process of restenosis (Figure 5) – are routinely inserted in the vessel.  
Initially, stents were only considered as a physical impediment to prevent   
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Figure 5: Schematic representation of a stented coronary artery 
 
restenosis; however in the last decade a new concept developed which 
saw stents as potential reservoir of specific drugs which could be released at 
the site of injury. This novel concept enabled the coating of stents with drugs 
such as rapamycin and paclitaxel, aimed at inhibiting the excessive 
proliferation and migration of vascular smooth muscle cells taking place after 
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stent deployment. In contrast to reduced restenosis rates, however, the 
frequency of stent thromboses has not decreased with the advent of drug-
eluting stents (DES) as compared with bare metal stents (Figure 6). For this 
purpose, in-stent thrombosis remains a major concern in modern clinical 
practice where DES are employed. This clinical setting prompted several 
investigators to look for the cause and explanation for the lasting occurrence 
of stent thromboses. Recently rapamycin, which is used for stent coating, was 
found to increase endothelial TF expression, suggesting a potential role for 
this drug in the development of subacute stent thrombosis (Steffel, Latini et al. 
2005; Zhu, Viswambharan et al. 2005). 
 
 
 
Figure 6: Slide presented by Pfisterer ME at the American College of Cardiology 2006. 
Outcome comparison between bare metal stents and drug eluting stents (DES). MI= 
myocardial infarction; TVR= target vessel revascularization; MACE= major adverse cardiac 
events. 
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Taking into consideration the above mentioned facts, the search for 
new strategies to inhibit directly or indirectly TF is vigorous. Various agents 
have been developed to specifically interfere with the action of TF and the 
TF/FVIIa complex (Steffel, Luscher et al. 2006). In contrast to classic 
antithrombotic drugs, these agents interfere with the upstream mediators of 
the coagulation cascade while leaving the downstream effectors intact. In 
addition, these drugs can target the promigratory and proproliferative effects 
of TF.  
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IV: Aims of the thesis. 
 
The aim of this thesis is to: 
 
1. Investigate the impact of paclitaxel –a drug commonly used for coating 
stents– on TF expression. 
  
2. Evaluate the potential of dimethyl sulfoxide as a novel agent to impair TF 
expression in vascular cells, inhibit thrombus formation and prevent vascular 
smooth muscle cells activation.  
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Material and Methods 
 
I: Cell culture and morphological assessment. 
 
Human aortic endothelial cells (HAEC) and VSMC (Clonetics, Allschwil, 
Switzerland) were cultured as described (Steffel, Akhmedov et al. 2005). THP-
1 cells (LGC Promochem, Molsheim, France) were cultured according to the 
supplier’s recommendation. Adhering cells were grown to confluence in 3 cm 
dishes and rendered quiescent for 24 hours before stimulation with 5 ng/mL 
TNF-α or 1 U/ml thrombin (both from Sigma, Basel, Switzerland) for 5 hrs. 
Cells were pretreated with Paclitaxel (Sigma and Alexis), Rapamycin or 
DMSO ( both from Sigma) for 1 h before stimulation. To block the mitogen-
activated protein (MAP) kinase p38, p44/42 (ERK), or c-Jun terminal NH2 
kinase (JNK), cells were treated with SB203580 (Sigma), PD98059 (Cell 
Signaling, Denvers, MA), or SP600125 (Calbiochem, Lucerne, Switzerland), 
respectively, for 60 minutes before stimulation. To assess cytotoxicity, a 
colorimetric assay for detection of lactate dehydrogenase (LDH) was used 
according to the manufacturer’s recommendations (Roche, Basel, 
Switzerland); in addition, trypan blue exclusion assay (0.4% solution, Sigma) 
and morphological examination by phase contrast microscopy (Leica, 
Glattbrugg, Switzerland) was performed. 
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II: Western blot analysis. 
 
Protein expression was determined by Western blot analysis as 
described (Steffel, Hermann et al. 2005). Cells were lysed in 50 mmol/L TRIS 
buffer, 25 µg were loaded per lane, and 10% SDS-PAGE was performed 
under reducing conditions. Resolved proteins were transferred to PVDF 
membranes (Millipore) by semidry transfer. The antibody against human TF 
(American Diagnostica) was used at 1:2’000 dilution; antibodies against 
phosphorylated p38 MAP kinase (p38), phosphorylated p44/42 MAP kinase 
(ERK), and phosphorylated c-jun terminal NH2 kinase (JNK) (all from Cell 
Signaling) were used at 1:1’000, 1:5’000, and 1:1’000 dilution, respectively. 
Antibodies against total p38, total ERK, and total JNK (all from Cell Signaling) 
were used at 1:2’000, 1:5’000, and 1:1’000 dilution, respectively. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used 
to ensure equal protein loading at an antibody (Chemicon) dilution of 
1:20’000. Proteins were detected with a horseradish peroxidase linked 
secondary antibody (Amersham). 
 
III: Real-time PCR. 
 
Total RNA was extracted with 1 mL TRIzol Reagent (Invitrogen) 
according to the manufacturer’s recommendations. Conversion of total cellular 
RNA to cDNA was carried out with Moloney murine leukemia virus reverse 
transcriptase and random hexamer primers (Amersham Bioscience) in a final 
volume of 33 µL using 4 µg of RNA. Real-time PCR amplification was 
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performed in an MX3000P PCR cycler (Stratagene) using the SYBR Green 
JumpStart kit (Sigma) in 25 µL final reaction volume containing 2 µl cDNA, 10 
pmol of each primer, 0.25 µl of internal reference dye, and 12.5 µl of 
JumpStart Taq ReadyMix (buffer, dNTP, stabilizers, SYBR Green, Taq 
polymerase, and JumpStart Taq antibody).(Bogdanov, Balasubramanian et al. 
2003) The total cDNA pool obtained served as template for subsequent PCR 
amplification with TF (F3)-specific primers (Sense primer: 5’-
TCCCCAGAGTTCACACCTTACC–3’; bases 508-529 of F3 cDNA; NCBI no. 
NM 001993; antisense primer: 5’–TGACCACAAATACCACAGCTCC–3’; 
bases 892-913 of F3 cDNA; NCBI no. NM 001993) using the following cycling 
parameters: 95° for 10 minutes for 1 cycle; 95° for 30 seconds, 60° for 1 
minute, 72° for 1 minute, for a total of 40 cycles. A melting curve analysis was 
performed after amplification to verify the accuracy of the amplicon. L28 
primers served as loading control. Products were separated by 
electrophoresis on a 1.6% agarose gel and visualized with ethidium bromide. 
 
IV: TF activity. 
TF cell surface and tissue activity was analyzed in HAEC and mouse 
carotid artery homogenates, respectively, using a colorimetric assay 
(American Diagnostica) according to the manufacturer’s recommendations 
with some modifications as described (Day, Reeve et al. 2005; Steffel, 
Akhmedov et al. 2005). Cells were grown in 6-well plates; after stimulation, 
cells were washed twice with PBS followed by incubation with human FVIIa 
and FX at 37° which allowed the formation of TF/FVIIa complex at the cell 
surface. Right carotid arteries were homogenized in 50 µl of lysis buffer (50 
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mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100 pH 7.4) and left to stand 
on ice for 30 minutes. TF/FVIIa complex converted human factor X to factor 
Xa, which was measured by its ability to metabolize a chromogenic substrate. 
A standard curve with lipidated human TF was performed to assure that 
measurements were taken in the linear range of detection. 
 
V: Carotid artery thrombosis model. 
 
The laser-injury thrombosis model was selected for this investigation 
since it has numerous advantages for the study of thrombosis in vivo. This 
model enables the examination of thrombus formation in live animals and 
does not require intravascular intrusion (Furie and Furie 2005). In addition, the 
precise location and initiation time of the injury is known. Figure 1 shows a 
schematic diagram of such injury model. 
 
 
 
 
 
 
Figure 1: Light-sensitive rose bengal was injected intravenously in the anesthetised mouse. 
Following midline cervical incision the right carotid artery was then exposed and a green laser 
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light was directed at it so as to elicit a photochemical reaction with the circulating rose bengal. 
Upon laser-induced photochemical injury of the vessel wall, vWF mediates the interaction of 
platelets with the endothelium. Tissue factor in the vessel wall leads to thrombin generation. 
Activated platelets undergo calcium mobilization and the release of ADP and thromboxane A2 
(TxA2) to accelerate platelet recruitment and activation and the formation of a platelet 
thrombus. These platelets express P-selectin, and leukocyte microparticles expressing PSGL-
1 and tissue factor accumulate in the. The concentration of tissue factor initiates coagulation, 
the generation of more thrombin, and the propagation of a fibrin clot (Figure and text adapted 
from J. Clin. Invest. 115:3355-3362 2005). 
 
C57BL/6 mice (6-8 weeks old) weighing an average of 23±2 g were 
anesthetized with intraperitoneal injection of 2 mg sodium pentobarbital 
(Butler, Columbus, OH) as previously described (Eitzman, Westrick et al. 
2000). Rose bengal (Fisher Scientific, Fair Lawn, NJ) was diluted to 10 mg/mL 
in phosphate-buffered saline and then injected into the tail vein in a volume of 
0.12 mL at a concentration of 50 mg/kg using a 27-gauge Precision Glide 
needle with a 1-mL latex free syringe (Becton Dickinson, Franklin Lakes, NJ). 
Mice were secured in a supine position, placed under a dissecting microscope 
(Olympus C-4040 Zoom; spatial resolution 4.1 megapixels), and the right 
common carotid artery was exposed following a midline cervical incision. A 
Doppler flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY, Figure 2 
left panel) was then applied and connected to a flowmeter (Transonic, Model 
T106, Figure 2 right panel).  
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: 
Figure 2: On the left, a perivascular doppler flow probe (Model 0.5 VB, Transonic Systems, 
Ithaca, NY) measuring flow on the right common carotid artery. On the right, a flowmeter 
(Transonic, Model T106) device. 
 
Six minutes after rose bengal injection, a 1.5-mW green light laser 
(540 nm) (Melles Griot, Carlsbad, CA) was applied to the desired site of injury 
at a distance of 6 cm for 60 minutes or until thrombosis occurred (depending 
on what elapsed first). From the onset of injury, blood flow in the vessel was 
monitored for 120 minutes, at which time the experiment was terminated. 
Occlusion was defined as a flow of ≤0.1ml/min for at least 1 minute (Eitzman, 
Bodary et al. 2003). Mice were divided into 3 groups: DMSO i.p. (1 hour 
before surgery, 3.8 ml/kg of 40% DMSO in PBS), PBS i.p. (1 hour before 
surgery, 3.8 ml/kg of PBS), and an additional control without laser injury. 
 
VI: Proliferation and migration of human aortic VSMC. 
For proliferation, VSMC were seeded at a density of 10,000 cells per 
  - 37 -
35-mm dish and cultured for 24 hours in DMEM with 10% FCS. Successively,  
 
cells were serum withdrawn in DMEM with 1% FCS for 48 hours. Cells were 
then maintained in DMEM with 10% FCS in the presence of different DMSO 
concentrations. Medium and appropriate DMSO concentrations were replaced 
daily and cell number was determined after 3 days by using a hemacytometer.  
For migration, VSMC were seeded at a density of 250,000 cells per 150-mm 
dish and cultured for 24 hours in DMEM with 10% FCS. Cells were then 
harvested and resuspended (500’000 cells/ml) for analysis of migration in 
response to PDGF 10 ng/ml. Migration was assessed in a modified Boyden 
chamber system (Neuroprobe Inc., Cabin John, MD) as previously described 
(Tanner, Largiader et al. 2004). The number of migrated cells was determined 
by staining (Diff-Quik; Dade Diagnostics Inc., Aguada, Puerto Rico) and 
counting the cells at 400× magnification (Leica, Glattbrugg, Switzerland) on 4 
random microscopic fields per group.  
 
VII: Statistical analysis. 
 
Data are reported as mean ± S.E.M. Unpaired Student t test was 
performed for statistical analysis. A p value <0.05 was considered to indicate 
a significant difference. 
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Results part I 
 
Preface. 
 
Percutaneous intervention is a common clinical practice employed for 
treating acute coronary syndromes (Grines, Cox et al. 1999; Lincoff, Califf et 
al. 1999). Drug-eluting stents (DES), which are coated with antiproliferative 
agents, improve the outcome after coronary artery stenting (Babapulle, 
Joseph et al. 2004). Paclitaxel (Figure 1), a microtubule-stabilizing drug 
eliciting cell cycle arrest in G2/M phase, is used on DES because it reduces 
vascular smooth muscle cell proliferation and migration (Sollott, Cheng et al. 
1995).  
 
 
 
 
 
 
 
 
 
Figure 1: Atomical structure of paclitaxel, molecular weight 853.  
 
Several randomised clinical trials have demonstrated that paclitaxel-
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eluting stents decrease restenosis. In contrast the use of DES has not 
reduced the occurrence of stent thrombosis as compared to bare metal stents 
(BMS) (Babapulle, Joseph et al. 2004; Eisenberg 2004; McFadden, Stabile et 
al. 2004; Stone, Ellis et al. 2004; Stone, Ellis et al. 2004). Acute, subacute, 
and late in-stent thrombosis has been observed in patients treated with 
paclitaxel-eluting stents and is associated with high morbidity and mortality 
(Ong, Hoye et al. 2005). 
Recently, rapamycin ( Figure 2), another drug used for DES, was 
shown to enhance endothelial TF expression (Steffel, Latini et al. 2005). The 
effect of paclitaxel on TF expression, however, is not known. The following 
experiments were therefore designed to investigate the effect of paclitaxel on 
TF expression in human endothelial cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Atomical structure of rapamycin, molecular weight 914. 
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I: Paclitaxel Enhances Endothelial Tissue Factor Expression.  
HAECs were stimulated with thrombin (1 U/ml) for 5 hours in the 
presence or absence of paclitaxel (10-9-10-5 mol/L). Thrombin induced a 20–
fold increase in TF expression as compared to baseline (n=7; P<0.0001; 
Figure 3A). One hour pretreatment with paclitaxel enhanced thrombin-induced 
TF expression in a concentration-dependent manner; a maximal effect 
occurred at 10-5 mol/L and resulted in a 2.1-fold induction as compared to 
thrombin alone, corresponding to a 43.3–fold induction as compared to 
baseline (n=6; P<0.0005; Figure 3A). The effect of paclitaxel was similar after 
a 1 hour as compared to a 25 hour pretreatment period (n=4; P=n.s. for 1 vs 
25 hours; Figure 3B). The effect of paclitaxel was first observed after 3 hours 
and elicited a significant increase in thrombin-induced TF expression after 5 
and 7 hours (n=4; P<0.05; Figure 5B). In another time course analysis, 
thrombin-induced TF expression was maximal after 6 hours of stimulation and 
decreased to 50% after 12 hours, 32% after 18 hours, and 27% after 24 
hours; paclitaxel significantly enhanced thrombin-induced TF expression by 
2.2–fold after 6 hours (n=4; P<0.05) and by 1.4–fold after 12 hours (n=4; 
P<0.05), while its effect did not reach statistical significance after 18 and 24 
hours (n=4; P=n.s.) (data not shown). Consistent with these observations, 
paclitaxel enhanced thrombin-induced TF surface activity by 56% (n=3; 
P<0.005; Figure 3C). Paclitaxel alone did not affect basal TF expression (n=7; 
P=NS; Figure 3A). Paclitaxel did not affect endothelial cell morphology (Figure 
4A) or LDH release (Figure 4B) at any concentration used (n≥5; P=NS). 
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Figure 3. Paclitaxel enhances thrombin-induced TF protein expression.  
A. Paclitaxel enhances thrombin-induced TF protein expression in a concentration-dependent 
manner (n=6; *P<0.0005 vs thrombin alone). Values are given as percent of TF expression in 
response to 5 hours thrombin stimulation. Blots are normalized to GAPDH expression. B. 
Similar effect of paclitaxel on thrombin-induced TF protein expression after 1 hour and 25 
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Figure 3. Paclitaxel enhances thrombin-induced TF protein expression.  
C. Paclitaxel enhances thrombin-induced TF surface activity (n=3; *P<0.005 vs thrombin 
alone). Values are given as percent of TF surface activity in response to 5 hours thrombin 
stimulation. 
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Figure 4. Lack of toxicity of paclitaxel.  
A. Morphology of HAECs after 5 hours thrombin stimulation is similar without (left panel) and 
with (right panel) paclitaxel (10-5 mol/L). Magnification x 50. B. LDH-release reveals no 
cytotoxic effect of paclitaxel on HAECs at any concentration used (n≥5; P=NS). 
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II: Paclitaxel enhances TF mRNA expression. 
Real-time PCR revealed that thrombin (1 U/ml) induced TF mRNA expression 
with a maximal effect occurring after 2 hours. Pretreatment with paclitaxel (10-
5 mol/L) enhanced thrombin-induced TF mRNA expression by 1.6–fold after 1 
hour (n=5; P<0.05; Figure 5A), by 1.5–fold after 2 hours (n=5; P=0.09; Figure 
5A), and by 1.7– fold after 3 hours (n=5; P=0.21; Figure 5A). The effect of 
paclitaxel on TF protein expression is time dependent (n=4; *P<0.05 vs 
thrombin alone; Figure 5B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Paclitaxel enhances thrombin-induced TF mRNA expression.                           
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A. Upper panel: Paclitaxel enhances thrombin-induced TF mRNA expression in a time-
dependent manner (n=5; P<0.05 vs thrombin alone). TF mRNA levels are normalized to L28; 
values are indicated as percent of TF mRNA expression induced by 2 hours thrombin 
stimulation. Lower panel: ∆∆CT values assessing the effect of paclitaxel on thrombin-induced 
TF mRNA expression at each time point (n=5; *P<0.05 vs thrombin alone). 
 
 
 
 
 
 
 
 
Figure 5. Paclitaxel time dependently enhances thrombin-induced TF expression. 
B. Western blot showing that the effect of paclitaxel on thrombin-induced TF protein 
expression is time-dependent. A significant increase is observed after incubation with 
paclitaxel for 5 and 7 hours (n=4; *P<0.05 vs thrombin alone). Values are given as percent of 
TF expression in response to 3 hours thrombin stimulation. Blots are normalized to GAPDH 
expression. 
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III: Paclitaxel selectively activates JNK. 
Thrombin 1U/ml induced a transient phosphorylation of the MAP kinases p38, 
ERK, and JNK. Maximal activation of JNK was observed after 60 minutes, 
while that of p38 and ERK occurred after 5 minutes. Paclitaxel 10-5 mol/L 
significantly increased JNK phosphorylation after 15, 30, and 60 minutes by 
3.7-, 3.2-, and 2.0–fold, respectively, as compared to thrombin alone (n=4; 
P<0.05 for each time-point; Figure 6A). Phosphorylation of p38 was slightly 
prolonged by paclitaxel 10-5 mol/L after 15 minutes of stimulation (n=4; 
P<0.005; Figure 6B), while all the other time-points remained unaltered (n=4; 
P=n.s.; Figure 6B). Phosphorylation of ERK was not affected by paclitaxel 
except for a slight decrease at the 5 minute time-point (n=4; P<0.01; Figure 
6C). Neither thrombin 1U/ml nor paclitaxel 10-5 mol/L altered total expression 
of MAP kinases.  
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Figure 6. Paclitaxel enhances thrombin-induced JNK activation.  
A. Paclitaxel (10-5 mol/L) enhances thrombin (1U/ml)-induced JNK activation after 15, 30, and 
60 minutes of stimulation (n=4; *P<0.05 vs thrombin alone). Expression of total JNK is not 
affected. B. Paclitaxel (10-5 mol/L) slightly prolongs maximal p38 phosphorylation. Expression 
of total p38 is not affected. C. Paclitaxel (10-5 mol/L) slightly decreases maximal ERK 
phosphorylation. Expression of total ERK is not affected.
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IV: Paclitaxel and docetaxel exert similar effects on TF and JNK. 
HAECs were stimulated with thrombin (1 U/ml) for 5 hours in the presence or 
absence of paclitaxel or docetaxel (respectively at 10-6 and 10-5 mol/L). 
Similar to paclitaxel, docetaxel enhanced thrombin-induced TF expression by 
2.2-fold as compared to thrombin alone (n=4; P<0.05 for thrombin plus 
paclitaxel vs thrombin alone; P<0.005 for thrombin plus docetaxel vs thrombin 
alone; P=NS for thrombin plus paclitaxel vs thrombin plus docetaxel; Figure 
7A). Docetaxel did not affect endothelial cell morphology nor LDH release at 
any concentration used (n=3; P=NS; data not shown). Similar to paclitaxel, 
docetaxel enhanced JNK phosphorylation as compared to thrombin alone. 
The increase in JNK activation after 2 hours of thrombin stimulation was 3.2–
fold for paclitaxel and 2.2–fold for docetaxel (n=4; P=0.0001 for thrombin plus 
paclitaxel vs thrombin alone; P<0.05 for thrombin plus docetaxel vs thrombin 
alone; P=NS for thrombin plus paclitaxel vs thrombin plus docetaxel; Figure 
7B). 
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Figure 7. JNK mediates the effect of paclitaxel and docetaxel on TF expression.  
A. Similar to paclitaxel, docetaxel (10-6 and 10-5 mol/L) enhances thrombin-induced TF 
expression (n=4; *P<0.05 for thrombin + paclitaxel vs thrombin alone; *P<0.005 for thrombin 
+ docetaxel vs thrombin alone; P=NS for thrombin + paclitaxel vs thrombin + docetaxel). 
Values are given as percent of TF expression in response to 5 hours thrombin stimulation. 
Blots are normalized to GAPDH expression. B. Paclitaxel and docetaxel enhance JNK 
phosphorylation as compared to thrombin alone (n=4; *P=0.0001 for thrombin + paclitaxel vs 
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thrombin alone; *P<0.05 for thrombin + docetaxel vs thrombin alone; P=NS for thrombin + 
docetaxel vs thrombin + paclitaxel). Expression of total JNK is not affected. C. SP600125 (10-
6 mol/L) reduces thrombin-induced TF expression to 65% of control (n=3; P<0.01). D. In the 
presence of SP600125 (10-6 mol/L), the effect of paclitaxel and docetaxel on thrombin-
induced TF expression is blunted (n=4; P<0.0001 for paclitaxel vs paclitaxel + SP600125; 
P<0.05 for docetaxel vs docetaxel + SP600125; P=NS for paclitaxel + SP600125 vs thrombin 
alone; P=NS for docetaxel + SP600125 vs thrombin alone). 
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V: JNK mediates the effect of paclitaxel and docetaxel on TF. 
HAECs were pretreated with SP600125, a specific inhibitor of JNK, 90 
minutes prior to stimulation with thrombin (1 U/ml). SP600125 (10-6 mol/L) 
reduced thrombin-induced TF expression by 35% (n=3; P<0.01; Figure 7C). 
Moreover, SP600125 reduced the effect of paclitaxel on thrombin-induced TF 
expression by 110% and that of docetaxel by 105%, respectively (n=4; 
P<0.0001 for paclitaxel vs paclitaxel plus SP600125; P<0.05 for docetaxel vs 
docetaxel plus SP600125; Figure 7D). Hence, inhibition of JNK by SP600125 
blunted the effect of paclitaxel and docetaxel on thrombin-induced TF 
expression (n=4; P=NS for paclitaxel plus SP600125 vs thrombin alone; 
P=NS for docetaxel plus SP600125 vs thrombin alone; Figure 7D). 
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Discussion part I 
 
This study reveals that paclitaxel enhances thrombin-induced 
endothelial TF protein expression and surface activity in a concentration- as 
well as time-dependent manner via its stabilizing effect on microtubules and 
selective activation of JNK. 
Paclitaxel is a lipophilic diterpenoid that binds to the β-subunit of the 
tubulin heterodimer; this interaction promotes tubulin polymerization leading to 
the formation of stable non-functional microtubule bundles and promoting cell 
cycle arrest in G2/M phase (Rowinsky and Donehower 1995; Crown and 
O'Leary 2000). Via this mechanism, paclitaxel inhibits proliferation as well as 
migration of vascular smooth muscle cells and reduces restenosis rates in 
patients with coronary artery disease (Sollott, Cheng et al. 1995; Babapulle, 
Joseph et al. 2004; Stone, Ellis et al. 2004). Due to its lipophilic properties, 
paclitaxel accumulates in the vessel wall reaching particularly high 
concentrations in the intima (Creel, Lovich et al. 2000; Levin, Vukmirovic et al. 
2004); local tissue concentrations are indeed 100-fold higher as compared to 
perfusate concentrations during ex vivo endovascular perfusion (Creel, Lovich 
et al. 2000). In a porcine coronary artery stent model, tissue concentrations of 
paclitaxel reached 3.2 µg/g of arterial tissue after 28 days and drop below 
detection limit within 3 months only (Vogt, Stein et al. 2004); this tissue 
concentration of paclitaxel corresponds to 3.7x10-6 mol/L at an assumed 
tissue density of 1 g/cm3 (Vogt, Stein et al. 2004). Similar tissue 
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concentrations have been measured in a rabbit iliac artery stent model (Finn, 
Kolodgie et al. 2005). Thus, the paclitaxel concentrations used in our study 
are comparable to local tissue concentrations after stent deployment.  
In animal models, partial reendothelialization has been observed as 
early as 4 days after DES deployment, while complete reendothelialization 
occurs within 3 weeks (Schwartz, Chronos et al. 2004; Vogt, Stein et al. 
2004). In humans, partial reendothelialization has been documented 2 weeks 
after stenting and is usually completed within 12 weeks (Grewe, Deneke et al. 
2000; Schwartz, Chronos et al. 2004). Paclitaxel-eluting stents have a 
biphasic drug release profile in vitro, characterized by an initial burst during 
the first 48 hours after implantation, followed by a sustained low-level release 
for at least 2 weeks (Colombo, Drzewiecki et al. 2003; Halkin and Stone 2004; 
Ranade, Miller et al. 2004). Due to its lipophilic properties, however, very high 
paclitaxel concentrations have been measured up to 4 weeks after stent 
implantation in vivo, and the drug remains detectable for up to 12 weeks. 
Therefore, the time course of reendothelialization coincides with the presence 
of paclitaxel in the vessel wall after stent deployment. Thus, paclitaxel may 
indeed alter the biology of the endothelium within the stented area. 
In-stent thrombosis has been described in patients treated with 
paclitaxel-eluting stents, particularly after cessation of antiplatelet therapy 
(McFadden, Stabile et al. 2004; Iakovou, Schmidt et al. 2005; Ong, McFadden 
et al. 2005). Our data demonstrate that the effect of paclitaxel is maintained 
over prolonged time periods and that it becomes effective as soon as a 
stimulus like thrombin is present; hence, the data are consistent with the 
clinical observation that cessation of antiplatelet therapy is a risk factor for 
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thrombosis of drug-eluting stents. Moreover, in view of the coronary paclitaxel 
concentrations after stent deployment as well as the time-course of 
reendothelialization, paclitaxel may indeed contribute to the development of 
subacute or late in-stent thrombosis by enhancing endothelial TF expression. 
This interpretation is supported by the results of the SCORE trial, which 
compared the QuaDDS stent (coated with the paclitaxel-derivative 7-
hexanoyltaxol) to BMS; the trial had to be terminated prematurely due to very 
high rates of subacute and late in-stent thrombosis as well as major adverse 
cardiac events (Grube, Lansky et al. 2004). The increased rates of in-stent 
thrombosis have been primarily related to the high paclitaxel doses released 
by these stents, while an unfavourable effect of the stent design may have 
contributed (Grube, Lansky et al. 2004). Interestingly, the paclitaxel-derivative 
7-hexanoyltaxol can be detected up to 10 mm proximal and distal to the stent 
margins, suggesting that paclitaxel may induce TF expression in the vessel 
segments proximal and distal to the stent as well (de la Fuente, Miano et al. 
2001). 
The effect of paclitaxel was due to a specific action on endothelial cell 
function as it did neither affect cell morphology nor induce any toxicity 
(Coomber and Gotlieb 1990; Blagosklonny, Darzynkiewicz et al. 2004). This is 
consistent with previous observations demonstrating that paclitaxel (10-5 
mol/L) does not induce any cell death in human pulmonary artery endothelial 
cells or aortic smooth muscle cells after 16 and 36 hours of incubation, 
respectively (Petrache, Birukova et al. 2003; Blagosklonny, Darzynkiewicz et 
al. 2004). The increase in TF surface activity was less pronounced than that in 
protein expression, which may be related to the presence of inactive 
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encrypted TF on the cell surface or to the distribution of TF in several cellular 
compartments (Schecter, Giesen et al. 1997). 
Thrombin induces TF expression at the transcriptional level via 
activation of the MAP kinases p38, ERK, and JNK (Liu, Pelekanakis et al. 
2004; Steffel, Latini et al. 2005). The increase in TF protein expression by 
paclitaxel was preceded by an enhanced TF mRNA expression. Consistent 
with this observation, paclitaxel augmented thrombin-induced JNK 
phosphorylation. Interestingly, the activation pattern of p38 and ERK was not 
affected, indicating that paclitaxel selectively activates JNK without affecting 
other signal transduction molecules in endothelial cells. Consistent with this 
interpretation, IkB-α degradation was not altered by paclitaxel. Similar 
observations have been made in different cancer cell lines, demonstrating that 
the effect of paclitaxel on JNK activation is not restricted to the endothelium 
(Lee, Li et al. 1998; Wang, Wang et al. 1998; Yujiri, Fanger et al. 1999). To 
assess whether JNK indeed mediates the induction of TF expression in 
response to thrombin and, in particular, to paclitaxel, endothelial cells were 
pretreated with SP600125, a selective inhibitor of JNK catalytic activity. 
SP600125 decreased thrombin-induced TF expression by about a third, 
indicating that JNK is not the only signal transduction mediator regulating 
thrombin-induced TF expression. In contrast, the JNK inhibitor fully prevented 
the effect of paclitaxel, strongly suggesting that the effect of paclitaxel on TF 
expression is selectively mediated by the JNK pathway. However, it can not 
be ruled out completely that other signal transduction pathways may be 
involved as well. 
The microtubule-stabilizing agent docetaxel was used to elucidate 
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whether the increase in thrombin-induced JNK activation and TF expression 
by paclitaxel was related to perturbation of microtubule function (Wang, Wang 
et al. 1998). Both microtubule-stabilizing agents exerted a similar effect on 
JNK activation and TF expression, and SP600125 blunted the enhancing 
effect of both docetaxel and paclitaxel on thrombin-induced TF expression. 
Thus, the action of paclitaxel on JNK activation and TF expression seems to 
depend on stabilization of microtubule bundles rather than on a substance-
specific effect. Consistent with this interpretation, JNK activation in response 
to changes in the microtubule cytoskeleton has been described in different 
cancer cell lines (Wang, Wang et al. 1998; Yujiri, Fanger et al. 1999). 
Paclitaxel enhanced thrombin-induced endothelial TF expression by 
2.1-fold. Rapamycin augmented thrombin-induced TF expression to a similar 
extent, while the mechanism of action of the two drugs differs completely; 
binding of rapamycin to its intracellular receptor FKBP-12 abrogates p70S6 
kinase phosphorylation leading to enhanced endothelial TF expression, while 
JNK activation remains unaffected (Steffel, Latini et al. 2005). Large-scale 
clinical trials have demonstrated that patients receiving paclitaxel-eluting 
stents have similar rates of in-stent thrombosis as compared to rapamycin-
eluting stents (Kastrati, Dibra et al. 2005; Windecker, Remondino et al. 2005). 
This observation is consistent with the similar degree of TF induction in 
endothelial cells, suggesting that the latter may indeed be importantly involved 
in thrombosis of DES. 
In conclusion, this study indicates that paclitaxel increases endothelial 
TF expression via JNK activation due to its microtubule stabilizing effect. The 
enhanced endothelial TF expression may favor thrombus formation after 
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paclitaxel-eluting stent deployment, particularly when antithrombotic drugs are 
withdrawn or thrombin levels are elevated as it occurs in acute coronary 
syndromes. Therefore, these findings may have interesting implications for 
drug-eluting stent design. 
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Results part II 
 
Preface. 
 
Dimethyl sulfoxide (DMSO, Figure 1) is employed for preservation of 
hematopoietic progenitor cells and therefore infused into patients undergoing 
bone marrow or stem cell transplantation (Egorin, Rosen et al. 1998).  
 
 
 
 
 
 
 
 
 
Figure 1: Atomical structure of DMSO, molecular weight 78. 
 
 
In this context, peak plasma concentrations reach values as high as 20 
mmol/L. DMSO is also used as a solvent for chemotherapeutic drugs and, 
due to its anti-inflammatory properties, has been successfully employed in 
humans for treating rheumatic (Morassi, Massa et al. 1989), pulmonary 
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(Iwasaki, Hamano et al. 1994), gastrointestinal (Salim 1992; Salim 1994), 
neurological (Karaca, Bilgin et al. 1991; Karaca, Kilic et al. 2002), urinary 
(McCammon, Lentzner et al. 1998), and dermatological (Wong and Lin 1988; 
Burgess, Hamner et al. 1998) disorders. DMSO further exhibits protective 
effects in animal models of middle cerebral artery occlusion (Bardutzky, Meng 
et al. 2005), cerebral hypoperfusion related neuronal death (Farkas, Institoris 
et al. 2004), mercuric chloride induced kidney injury (Jo, Hu et al. 2004), and 
chemical liver injury (Lind and Gandolfi 1997). A recent report proposed that 
DMSO reduces ischemic brain damage through both anti-inflammatory and 
free radical scavenging properties (Bardutzky, Meng et al. 2005). Despite of 
all this information, the impact of DMSO on cardiovascular disorders has not 
been assessed. 
Since intravenous delivery of DMSO has become a recognized practice 
in clinical oncology due to the increasing use of bone marrow transplants, this 
study was designed to investigate the impact of DMSO on TF expression and 
thrombosis as well as on activation of VSMC. 
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I: Dimethyl Sulfoxide Inhibits Tissue Factor Expression. 
 
Stimulation of HAEC with TNF-α (5 ng/ml) resulted in a 19-fold 
increase in TF expression (n=4; P<0.0001; 2A); similarly, thrombin (1 U/mL) 
induced a 24-fold increase of TF (n=4; P<0.0001; 2B). When cells were 
pretreated with increasing concentrations of DMSO (0.1-1.0%), TF induction 
by both TNF-α and thrombin was inhibited in a concentration-dependent 
manner (n=4; P<0.0001 for TNF-α or thrombin alone vs. 1.0% DMSO; 2A, 
2B). This effect was paralleled by a similar inhibition of TF surface activity 
(n=4; P<0.0001 for TNF-α alone vs. 1.0% DMSO; 2C). In THP-1 cells, 
stimulation with TNF-α (5 ng/ml) induced a 10-fold increase in TF expression 
(n=4; P<0.0001), which was inhibited by DMSO (n=4; P<0.005 for TNF-α 
alone vs. 1.0% DMSO; Fig. 2D). In VSMC, the 3.5-fold increase in TNF-α-
induced TF expression (n=4; P<0.005) was inhibited as well by DMSO (n=4; 
P<0.05 for TNF-α alone vs. 1.0% DMSO; Fig. 2D). 
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Figure 2. DMSO inhibits TF expression and activity.  
A. DMSO inhibits TNF-α induced TF expression of human aortic endothelial cells (HAEC) in a 
concentration-dependent manner. Values are given as percent of stimulation with TNF-α 
alone. *P<0.001, ** P<0.0001 vs. TNF-α alone. B. DMSO inhibits thrombin-induced TF 
expression of HAEC in a concentration-dependent manner. Values are given as percent of 
stimulation with thrombin alone. *P<0.001, ** P<0.0001 vs. thrombin alone. C. DMSO inhibits 
TNF-α induced TF surface activity of HAEC. Values are given as percent of stimulation with 
TNF-α alone. ** P<0.0001 vs. TNF-α alone. D. DMSO inhibits TNF-α induced TF expression 
in a concentration-dependent manner in HAEC, human monocytic cells (THP-1) and in 
human aortic vascular smooth muscle cells (VSMC). Values are representative of at least 3 
different experiments; all blots are normalized to GAPDH expression 
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II: DMSO does not exert toxicity in human vascular cells.  
 
To assess potential toxic effects of DMSO, HAEC were incubated with 
1.0% DMSO for 6 hours, and a morphological examination was performed. No 
changes in cell morphology were observed when cells with or without 
treatment were compared (Fig. 3A). In addition, cell death was assessed by 
both LDH release and trypan blue exclusion in HAEC; again, no signs of  
toxicity were detected by either method (n=4; P=n.s.; Fig. 3B, 3C).  
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Figure 3. Lack of DMSO-induced toxicity.  
A. Incubation with DMSO for 6 h does not affect cell morphology (20 times magnification). 
LDH release (B) and the number of trypane blue positive cells (C) remains unaffected by 
different DMSO concentrations as well. Values are given as percent of stimulation with TNF-α 
alone 
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III: DMSO inhibits TF mRNA expression  
 
Peak induction of TF mRNA occurs 2 hours after stimulation with TNF-
α (Steffel, Latini et al. 2005). Real-time PCR analysis confirmed a 10-fold 
induction of TF mRNA expression after 2 h of TNF-α stimulation in HAEC 
(n=3; P<0.001; Fig. 4A). Treatment with 1.0% DMSO inhibited TF mRNA 
expression by 65±7% (n=3; P<0.0001 for TNF-α alone vs. 1.0% DMSO; Fig. 
4A, 4B).  
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Figure 4. DMSO inhibits TF mRNA expression.  
A. Real-time PCR demonstrates increased TF mRNA expression after 2 h of stimulation with 
TNF-α. DMSO inhibits this effect. Values are given as percent of stimulation with TNF-α 
alone. *P<0.001 vs. TNF-α alone. B. ∆∆CT values confirm that DMSO decreases TNF-α 
induced TF mRNA expression. ** P<0.0001 vs. TNF-α alone. All values are representative of 
4 different experiments and are normalized to L28 mRNA. 
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IV: DMSO impairs TF expression via MAPK inhibition 
 
To assess whether DMSO affects MAP kinase activation, HAEC were 
examined at different time points after stimulation. JNK, p38, and ERK were 
transiently activated by TNF-α (Fig. 5A). Maximal phosphorylation occurred 
after 15 minutes and returned to basal levels within 60 minutes (Fig. 5A). 
DMSO inhibited phosphorylation of JNK and p38 by over 50% while leaving 
activation of ERK unaltered (Fig. 5A). Indeed, maximal phosphorylation of 
JNK was decreased by 51±6% (n=4; P=0.0005; Fig. 5B) and that of p38 by 
50±3% (n=4; P<0.0001; Fig. 5B); in contrast, maximal activation of ERK was 
not significantly reduced (n=4; P=n.s.; Fig. 5B). No change in total expression 
of JNK, p38, or ERK was observed at any time point with or without DMSO. 
To verify the involvement of MAP kinases in TNF-α-induced TF expression 
under our experimental conditions, the effect of MAP kinase inhibitors on TF 
expression was examined in HAEC. SP600125, SB203580, and PD98059, 
which specifically inhibit JNK, p38, and ERK, respectively, significantly 
impaired TF induction after TNF-α stimulation (n=4; P<0.001 for TNF-α alone 
vs. each inhibitor; Fig. 5C). 
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Figure 4. DMSO inhibits MAP kinase activation.  
A. Stimulation with TNF-α leads to transient phosphorylation (Pho) of the MAP kinases JNK, 
p38, and ERK. DMSO inhibits phosphorylation of JNK and p38, but not ERK. Total (Tot) 
levels of JNK, p38, and ERK remain unchanged. 
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Figure 4. DMSO inhibits MAP kinase activation.  
B. DMSO strongly inhibits phosphorylation of JNK and p38, but not ERK. Average values of 4 
different experiments. *P<0.001, for JNK and p38 vs. TNF-α alone C. SP600125, SB203580, 
and PD98059, specific inhibitors of JNK, p38, and ERK, respectively, inhibit TNF-α induced 
TF expression. *P<0.001, vs. TNF-α alone. Blots are representative of at least 3 different 
experiments. 
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V: DMSO does not affect TFPI and PAI-1 expression  
 
The effect of DMSO on the physiological inhibitor of TF, TFPI, as well 
as on the anti-fibrinolytic factor, PAI-1, was assessed. Treatment of TNF-α-
stimulated HAEC with 1% DMSO did not affect TFPI expression (n=4; P=n.s.; 
Fig. 6A). Similarly, treatment of TNF-α-stimulated HAEC with 1.0% DMSO did 
not alter PAI-1 expression (n=4; P=n.s.; Fig. 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. DMSO does not affect TFPI and PAI-1 expression.  
A. DMSO does not affect TFPI expression p<0.2. 
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Figure 6. DMSO does not affect TFPI and PAI-1 expression.  
B. PAI-1 expression is induced by TNF-α stimulation**P<0.0001 vs. TNF-α alone. DMSO 
does not affect TNF-α induced PAI-1 expression. Values are given as percent of stimulation 
with TNF-α alone. Blots are representative of at least 3 different experiments. 
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VI: DMSO suppresses TF activity and prevents arterial thrombosis 
in vivo 
 
Treatment with DMSO (3.8 ml/kg of 40% DMSO in PBS corresponding 
to 80 mg/kg of DMSO) reduced TF activity in mouse carotid artery in vivo 
(n=3; P<0.002 for vehicle (PBS) vs. DMSO; Fig. 7A).  
Photochemically induced arterial injury is dependent on TF and is an 
established model of arterial thrombosis (Matsuno, Uematsu et al. 1991). 
Initial blood flow in vehicle (PBS)-treated mice equalled 1.25±0.15 ml/min 
(n=5); these mice developed thrombotic occlusion within 1 hour after onset of 
injury (mean occlusion time 63±9 minutes; n=5; P<0.0001 for initial vs. final 
blood flow; Fig. 7B). During injury, it was evident from transient reductions in 
flow that a dynamic state of thrombus formation and lysis occurred during the 
short time interval prior to complete occlusion. Cessation of blood flow 
coincided with the appearance of a faint white occlusive defect that was visible 
through the microscope in the lumen of the artery. DMSO (3.8 ml/kg of 40% 
DMSO in PBS corresponding to 80 mg/kg of DMSO) treated mice exhibited 
similar initial blood flow (1.14±0.19 ml/min; n=5; P=n.s. for vehicle vs. DMSO), 
but did not develop thrombotic occlusion. Indeed, 120 min after onset of 
injury, blood flow in DMSO-treated mice was still very high (0.75±0.15 ml/min; 
n=5; P<0.01 for vehicle vs. DMSO). However, DMSO-treated mice exhibited a 
small, but significant decrease in blood flow during the 120 minutes 
observation period as compared to control mice who did not undergo 
photochemical injury (n=5; P<0.05). Blood flow in the latter did not change 
significantly during the 120 minutes observation period (initial flow: 1.12±0.17 
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Figure 7. DMSO inhibits carotid artery TF activity and prevents thrombotic occlusion in 
a mouse model of photochemical injury.  
A. DMSO inhibits TF activity in mouse carotid artery. Values are given as absorbance at 405 
nm. ** P<0.0001 vs. PBS treated (vehicle).    
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Figure 7. DMSO inhibits carotid artery TF activity and prevents thrombotic occlusion in 
a mouse model of photochemical injury.  
B. Transit-time flow recordings of vehicle treated (PBS) or DMSO treated mouse carotid 
artery after photochemical injury in vivo. Laser injury is initiated at time = 0 min. Uninjured 
mice are included as an additional negative control. DMSO prevents thrombus formation 
(P=0.0090 for DMSO treated vs. vehicle treated; P=0.002 for DMSO treated vs. negative 
control). 
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VII: DMSO inhibits proliferation and migration of human VSMC  
 
Treatment with DMSO inhibited VSMC proliferation in response to 20% 
FCS in a concentration-dependent fashion (n=4; P<0.05; Fig. 8A). Likewise, 
DMSO inhibited VSMC migration in response to 10 ng/ml PDGF BB (n=4; 
P<0.05; Fig. 8B). Both rapamycin and paclitaxel are known to enhance 
thrombin-induced TF expression(Steffel, Latini et al. 2005; Stahli Barbara 
2006). To determine whether DMSO can prevent this effect, HAEC were 
incubated with either drug with or without DMSO (Fig. 8C). Rapamycin (10-7 
M) and paclitaxel (10-5 M) enhanced thrombin-induced TF expression by 
241.9±54.61% (n=4; P<0.05 vs. thrombin alone; Fig. 8C) and 184±35.3% 
(n=4; P<0.05 vs. thrombin alone; Fig. 8C), respectively. DMSO blunted the 
effect of rapamycin and paclitaxel on TF expression (n=4; P=<0.0001 vs. 
thrombin plus rapamycin or thrombin plus paclitaxel; Fig. 8C).  
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Figure 8. DMSO inhibits proliferation and migration of VSMC 
A. DMSO inhibits VSMC proliferation in response to 20% FCS by 70%; n=4 *P<0.05 vs. 
control. B. DMSO inhibits VSMC migration in response to 5 hours 10 ng/ml PDGFstimulation 
by 75%; n=4*P<0.05 vs. control. Values are given as percent of stimulation with TNF-α alone. 
** P<0.0001 vs. TNF-α alone. 
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Figure 8. DMSO prevents paclitaxel- and rapamycin-enhanced TF expression 
C. Paclitaxel and rapamycin enhance thrombin-induced TF expression in HAEC (n=4; 
*P<0.05 for rapamycin or paclitaxel vs. thrombin alone). DMSO blunts thrombin-induced TF 
expression as well as the effect of rapamycin and paclitaxel on TF expression. ** P<0.0001 
vs. DMSO, DMSO plus rapamycin, and DMSO plus paclitaxel. Blots are representative of 4 
different experiments. 
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Discussion part II 
  
This study demonstrates that DMSO inhibits TF expression and activity 
via reduced activation of the MAP kinases JNK and p38. Consistent with this 
observation, DMSO suppresses TF activity and protects from thrombotic 
occlusion in vivo. The study also demonstrates that DMSO inhibits 
proliferation and migration of vascular smooth muscle cells; furthermore, it 
prevents TF induction in response to rapamycin and paclitaxel. This profile 
renders DMSO ideally suitable for application on drug-eluting stents and for 
the treatment of acute coronary syndromes. 
DMSO treatment did not exert any toxic effect even at the highest 
concentration used (1.0%; 12.6 mmol/L). An extensive study in human 
endothelial cells also did not observe any toxic effects of DMSO even at 
concentrations well above those employed in our study (Bourne, Shearer et 
al. 1994). Moreover, DMSO has been routinely used to trigger in vitro cellular 
differentiation at concentrations as high as 1.25% (15.7 mmol/L) (Heidari, 
Shah et al. 2004). Furthermore, in patients after myeloablative therapy, 
DMSO is infused intravenously together with hematopoietic progenitor cells; 
under these conditions, DMSO reaches plasma concentrations of 1.6% (20.0 
mmol/L) and only rarely causes adverse effects (Egorin, Rosen et al. 1998). 
Thus, the DMSO concentrations applied in our study are clearly below those 
used to induce cellular differentiation or those occurring in treatment of 
leukaemia patients and hence would be suitable for clinical use. 
Thrombin and TNF-α induced TF expression in HAEC with similar 
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potencies, and incubation with DMSO suppressed this effect irrespective of 
the stimulus. Furthermore, DMSO reduced TNF-α-induced TF expression not 
only in HAEC, but also in THP-1 and VSMC, indicating that the effect on TF 
occurs irrespective of the cell type. Therefore, the protective action of DMSO 
is neither restricted to a specific stimulus nor to a specific vascular cell type. 
Activation of MAP kinases mediates TF expression in response to 
several stimuli (Mechtcheriakova, Schabbauer et al. 2001; Eto, Kozai et al. 
2002; Steffel, Akhmedov et al. 2005; Steffel, Hermann et al. 2005). Indeed, 
JNK, p38, and ERK were transiently activated in HAEC after stimulation with 
either TNF-α or thrombin. Treatment with DMSO impaired TF expression by 
specifically decreasing phosphorylation of JNK and p38, but not ERK; hence, 
inhibition of these two MAP kinases suppressed TF expression in a potent 
manner. In line with this observation, pharmacological inhibition of the two 
MAP kinases induces a more pronounced reduction of TF expression than 
inhibition of one MAP kinase alone. Consistent with inhibition of MAP kinases, 
DMSO promoted a strong reduction in TNF-α-induced TF mRNA levels. Thus, 
the inhibitory action of DMSO is related to a specific inhibition of MAP kinase 
activation. 
TF activity is counterbalanced by its endogenous inhibitor TFPI; the 
balance of these two factors is essential in determining thrombus formation 
(Pedersen, Holscher et al. 2005). Treatment with DMSO did not affect TFPI 
expression indicating that the antithrombotic action of DMSO on TF 
expression is not compensated by a concomitant reduction in TFPI 
expression. PAI-1 is a serpin that suppresses fibrinolysis by inhibiting the 
activity of plasminogen activator. A recent report demonstrated that DMSO is 
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able to reduce interleukin-1-induced PAI-1 expression in rat microvascular 
endothelial cells (Okada, Woodcock-Mitchell et al. 1998). In contrast, we did 
not observe any effect of DMSO on PAI-1 expression in TNF-α-stimulated 
HAEC; this difference may be related to the different species, the different 
origin of the cells, or the different stimuli used for induction. Thus, the 
inhibitory action of DMSO on TF expression does not seem to be modulated 
by concomitant effects on TFPI or PAI-1. 
It is generally accepted that thrombus formation is triggered by TF 
(Nemerson 1988; Mann, van't Veer et al. 1998; Mackman 2004). 
Photochemical injury was selected as a model of thrombosis because it is an 
established protocol for examining TF-dependent thrombosis in vivo (Day, 
Reeve et al. 2005); moreover, this procedure does not require intra-arterial 
invasion (Matsuno, Uematsu et al. 1991; Day, Reeve et al. 2004). We 
observed that thrombotic occlusion following injury was prevented in DMSO-
treated mice, indicating that treatment with DMSO prevents thrombus 
formation in vivo. Indeed, inhibition of TF activity in the mouse carotid artery 
within 2 hours of DMSO administration was confirmed and thus is the most 
likely explanation for the effect of DMSO on thrombus formation after 
photochemical injury. It can not be excluded, however, that the effects of 
DMSO in vivo may in part be attributable to its ability to impair platelet 
adherence and aggregation (Dujovny, Rozario et al. 1983).  
Involvement of TF in acute coronary syndromes was recently 
underlined by a study revealing increased levels of TF antigen and activity in 
atherectomy specimens from patients with unstable angina or myocardial 
infarction as compared to those with stable angina (Annex, Denning et al. 
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1995). Moreover, in acute coronary syndromes, plasma concentrations of 
cytokines such as TNF-α and interleukin-6 are increased at the site of 
coronary artery occlusion to concentrations high enough to induce TF in 
vascular cells (Maier, Altwegg et al. 2005). For these reasons, inhibition of TF 
by DMSO may represent a novel and promising strategy for targeting 
thrombosis in acute coronary syndromes. In addition, the antiproliferative and 
antimigratory properties of DMSO as well as its common use in clinical 
practice underscore its suitability for administration to patients with acute 
coronary syndromes either intravenously or locally as a coating agent for drug 
eluting stents.  
Although drug-eluting stents are effective in reducing restenosis rates 
after percutaneous coronary intervention through inhibition of neointima 
formation and constrictive remodelling, stent thrombosis remains a concern 
with these devices. Indeed, the rate of stent thrombosis observed with drug-
eluting stents is around 2% in controlled clinical trials and may be higher in 
“real world” patients (Iakovou, Schmidt et al. 2005; Windecker, Remondino et 
al. 2005). Moreover, if thrombosis of such stents occurs, it is associated with a 
high morbidity and mortality (Ong, Hoye et al. 2005). Our study demonstrates 
that DMSO has the potential to inhibit both neointima formation and stent 
thrombosis if applied on a drug-eluting stent. The known ability of DMSO to 
inhibit platelet aggration may be very important in this context as well 
(Dujovny, Rozario et al. 1983). The ability of DMSO to suppress rapamycin 
and paclitaxel-induced TF expression is of particular relevance, as this effect 
of rapamycin and paclitaxel represents a possible cause for the occurrence of 
stent thrombosis in drug-eluting stents (Steffel, Latini et al. 2005; Stahli 
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Barbara 2006). Indeed, DMSO could be applied on such stents either alone or 
in combination with rapamycin or paclitaxel; such an application is technically 
feasible and looks particularly promising. 
In summary, this study provides evidence that DMSO specifically 
suppresses TF expression and activity in addition to preventing TF-dependent 
thrombosis in vivo; furthermore, DMSO inhibits proliferation and migration of 
VSMC and prevents rapamycin as well as paclitaxel-induced TF expression. 
As the use of DMSO is established in different areas of modern medicine, we 
propose this drug as a novel strategy for treating acute coronary syndromes; 
in particular, DMSO seems to represent an attractive compound for 
application on drug-eluting stents, either alone or in combination with 
rapamycin or paclitaxel.  
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Conclusions 
 
Expression of TF is an important defence mechanism that evolved to 
prevent excessive bleeding and promote wound repair. Yet, TF expression 
has been shown to be crucially involved in cardiovascular disease.   
Taken together, our work shows that TF expression is importantly 
regulated by the phosphorylation of the MAP kinases JNK, ERK and p38 
(Figure 1). However, TF expression can also take place to a lesser extent 
when only one or two MAP kinases are activated. 
Paclitaxel, an agent universally used to coat stents and target 
restenosis is indeed very effective at doing so but, as an unwanted effect, it 
induces TF expression by activation of the MAP kinase JNK (Figure 1). This 
finding could partly account for the recurrence of in stent thrombosis which, 
despite the advent of drug eluting stents, remains a central negative outcome 
in present-day clinical practice. The notion that rapamycin, likewise paclitaxel, 
induces TF expression, makes the search for a new compound a pressing 
issue.  
DMSO inhibits TF expression in human vascular cells as well as 
preventing thrombosis in the mouse. In addition, DMSO inhibits the activation 
of human smooth muscle cells; a key process implicated in restenosis. 
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Figure 1: Schematic diagram representing MAP Kinases mediation of TF expression. 
Paclitaxel enhances TF expression by increasing JNK activation while DMSO prevents TF 
expression by inhibiting JNK and p38 activation. 
 
As the use of DMSO is established in different areas of modern 
medicine, we propose this drug as a novel strategy for treating acute coronary 
syndromes; in particular, DMSO seems to represent an attractive compound 
for application on drug-eluting stents, either alone or in combination with 
rapamycin or paclitaxel.  
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